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Effective suppression of parathyroid hormone by la-hydroxy-vitamin
D2 in hemodialysis patients with moderate to severe secondary hyper-
parathyroidism. Calcitriol, as used for treating secondary hyperparathy-
roidism, has a low therapeutic index. The safety and efficacy of the vitamin
D analog, la(OH)-vitamin D2 (laD2), which has less toxicity in animals
than la(OH)-vitamin D3, was tested in a multicenter study of 24 hemo-
dialysis patients with secondary hyperparathyroidism [serum intact (i)
PTH > 400 pg/mI]. Calcium-based phosphate binders alone were used to
maintain serum phosphorus  6.9 mg/dl. After eight weeks without
calcitriol (washout), oral laD2, 4 rg/day or 4 g thrice weekly, was started,
with the dose adjusted over 12 weeks to maintain serum iPTH between
130 and 250 pg/mI. Pre-treatment serum iPTH fell from 672 70 pg/mI
(SCM) to 289 36 after treatment (P < 0.05). The maximal decrease in
serum iPTH was 48 to 96%, with 87.5% of patients reaching target iPTH
levels. The final dose of laD2 averaged 14.2 rgIweek. Pre-treatment
serum calcium rose modestly from 8.8 0.2 mg/dl to 9.5 0.2 after
treatment (P < 0.001). Only once did modest hypercalcemia (serum Ca >
11.2 mg/dl) necessitate stopping treatment. Neither the average serum P
level, the incidence of hyperphosphatemia, nor the dose of phosphate
binders changed from washout to treatment. Thus, oral laD2 is highly
efficacious in suppressing secondary hyperparathyroidism in hemodialysis
patients and is safe despite exclusive use of calcium-based phosphate-
binders. Future studies should clarify the optimal dosage regimen.
The pathogenesis of secondary hyperparathyroidism associated
with chronic renal failure is complex, but a relative or absolute
deficiency of calcitriol is one of the major contributing factors [1].
The reduction in blood calcitriol level that occurs with advanced
renal insufficiency reduces calcium absorption by the intestine,
hence lowering the plasma calcium level and thereby indirectly
stimulating secretion of parathyroid hormone (PTH), In addition,
calcitriol is known to act directly on the parathyroid glands
through specific vitamin D receptors to suppress the transcription
of mRNA for prepro-PTH [2, 3], which is an early step in PTH
synthesis. Therefore, a deficiency of calcitriol directly leads to
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increased PTH secretion due to the loss of the inhibitory action of
calcitriol on the parathyroid gland.
Calcitriol has been used extensively to treat dialysis patients
with secondary hyperparathyroidism; however, the side-effects of
hypercalcemia and hyperphosphatemia usually limit its use. Thus,
the therapeutic index for calcitriol in suppressing PTH secretion is
quite low.
Efforts have been made to identify analogues of vitamin D that
would have a similar suppressive effect on PTH secretion but
produce less hypercalcemia [4—6]. One potential candidate is
la-hydroxy-vitamin D2 (lcxD2). In vitamin D-deflcient rats, this
sterol is equipotent to la-hydroxy-vitamin D3 (laD3) in stimulat-
ing intestinal Ca transport, mobilizing bone Ca, and producing
healing of rickets [7]; however, much larger doses of laD2 than
laD3 are required to produce hypercalcemia and toxicity in both
normal rats [8] and normal mice [9]. Both laD2 and laD3 are
metabolized by the liver to form, respectively, la,25(OH)2D2 and
la,25(OH)2D3, the active forms of these sterols. Previous expe-
rience with icsD2 in humans has been limited to trials in normal
young men (unpublished data) and postmenopausal women [10];
under these circumstances, mild increases in urinary calcium were
observed with 4.0 .rg/day, however, hypercalciuria occurred only
at doses of 5
.tg/day or greater.
The purpose of the present study was to evaluate the safety and
efficacy of I aD2 in suppressing serum iPTH levels in hemodialysis
patients with moderate to severe secondary hyperparathyroidism.
The results demonstrate that this vitamin D analog is highly
effective in lowering serum intact PTH (iPTH) levels with a very
low incidence of hypercalcemia and hyperphosphatemia.
Methods
Patients with moderate to severe secondary hyperparathyroid-
ism, defined as having a serum iPTH above 400 pg/mI, were
recruited from the West Los Angeles VA Medical Center, South
Valley Regional Dialysis Center and BMA Culver City Dialysis
Unit. The protocol was approved by the committee for human
studies at each institution, and informed consent was obtained
from each patient.
The study consisted of an 8-week washout period followed by a
12-week treatment period. Criteria for inclusion into the washout
period of the study were: (1) a duration of hemodialysis greater
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than four months; (2) evidence of a serum iPTH value above 400
pg/mi while not receiving therapy with calcitriol, (3) a serum
albumin level greater than 3.5 g/dl, (4) an average serum phos-
phorus between 3.0 and 6.9 mg/di over the preceding two months,
(5) no intake of aluminum-containing phosphate binders within
the last 12 months, and (6) a serum aluminum level below 40
sg/ml.
Criteria for exclusion included: (1) any underlying medical
condition, such as malabsorption syndrome or severe liver disease,
that might alter the absorption or metabolism of 1sD2; (2) any
condition that may have precluded a patient from remaining in
the study, such as alcohol/drug abuse, malignancy, or psychiatric
disorder; and (3) parathyroid surgery within the previous 12
months.
Biochemical measurements
During the washout period, serum calcium (Ca) and phospho-
rus (P) were monitored weekly, and serum iPTH levels were
measured every two weeks. During the treatment period, these
measurements were done weekly or biweekly. Serum levels of
lcx,25(OH)2D2 and la,25(OH)2D3 were measured at the begin-
fling and end of the washout period and every two to four weeks
during the treatment period. All blood samples were obtained
immediately before the hemodiaiysis procedure.
During the 8-week washout period, calcitriol therapy was
discontinued. The patients underwent dialysis for three to four
hours, three times/week, utilizing a dialysate Ca concentration of
2.5 mEq/liter. Throughout the entire study, calcium carbonate
and/or calcium acetate were the only phosphate-binding agents
utilized. On completing the washout period, patients were eligible
to enter into the 12 weeks treatment phase if: (1) a serum iPTH
value exceeded 400 pg/mI during the washout period, and (2) the
average serum phosphorus level was less than or equal to 6.9
mg/dl during the washout period.
Dosage of 1 aD2 and dosage adjustment
Qualified patients were initially given laD2 orally, either 4 jig
each morning (10 patients) or 4 jig, three times per week at the
end of hemodialysis (14 patients). The frequency of the initial
dose depended on several factors, including the serum iPTH level
during washout, and/or a history of previous treatment with high
doses of calcitriol. Subsequently, the dose of laD2 was adjusted to
achieve a serum iPTH level within the specific target range of 130
to 250 pg/mI. This serum iPTH range was chosen because it is
most commonly associated with normal rates of bone turnover in
patients with end-stage renal disease [11—141. The treatment with
I aD2 was stopped in patients whose serum IPTH decreased below
130 to 150 pg/mI. When this occurred, the serum iPTH was
monitored weekly until it rose above 300 pglml, at which time
treatment with laD2 was resumed at a dose reduced by one step
(Table I). If the serum iPTI{ simply decreased into the target
range (130 to 250 pg/mi), the laD2 dosage was reduced by one
step without interruption. In patients initially treated with 4 jig
three times weekly, the dosage was increased to 4 jig daily if the
serum iPTH failed to fall by more than 25% within six to eight
weeks (6 patients). Treatment with laD2 was also slopped in
patients who developed marked hypercalcemia, defined as a
serum Ca above 11.2 mg/dl, or marked hyperphosphatemia,
defined as a serum P above 8.0 mg/dl. When this occurred, serum
Ca and P were monitored twice weekly until the serum Ca fell to
Table 1. Dosing schedule with In-hydroxy-vitamin D2
Initial dosing 4 jig per day, before breakfast (10 patients)
or
4 jig, 3 times per week, after hemodialysis
(14 patients)
1st Reduction 4 jig, 3 times per week, after hemodialysis
or
4 jig, twice per week, after hemodialysisa
2nd Reduction 4jig, twice per week, after hemodialysis
or
4 jig, once per week, after hemodiaiysis
3rd Reduction 4 jig, once per week, after hemodialysis
In patients treated earlier with 4 jig, 3 times per week, after hemodi-
alysis
10.2 mg/dl or below or serum P fell to 6.9 mg/dl or below; then, the
treatment with laD2 was resumed at a dose reduced by one step
(Table 1).
If the patient developed mild hypercalcemia, defined as a serum
Ca of 10.3 to 11.2 mg/dl and the serum P level was below 6.9
mg/dl, the dose of the phosphate binder was reduced. The dose of
phosphate binder was increased if mild hyperphosphatemia, de-
fined as a serum P of 7.0 to 8.0 mg/dl, developed in the face of a
serum Ca of 10.2 mg/dl or below. If mild hypercalcemia or
hyperphosphatemia persisted despite these measures, the dose of
laD2 was reduced by one level (Table 1).
Thirty-nine patients entered the washout period, and 27 qual-
ified to enter into the treatment period; 24 of these 27 patients
completed the study. Only the data from the patients completing
the 12-week treatment period were included in the statistical
analysis. Three patients were dropped from the study: One patient
refused to continue "taking all the pills;" another patient was
dropped because she was substantially non-compliant with taking
her phosphate-binding agents and developed persistent hyper-
phosphatemia; the third received a kidney transplant after seven
weeks of treatment. Of the 24 patients who finished the study, 18
were men and 6 women; their ages ranged from 27 to 74 years
(mean of 51 years), and the duration of dialysis averaged 28
months (range of 4 to 162 months). Eighteen patients had
previously been treated with calcitriol, while 6 patients had never
received calcitriol. The causes of renal failure included: hyperten-
sive nephrosclerosis in 10 patients; glomerulonephritis in 7;
diabetic nephropathy in 2; a combination of hypertension and
diabetes in 2; systemic lupus erythematosus in 2; and polyarteritis
nodosa in one.
All blood specimens for biochemistry and serum iPTT-t were
processed and analyzed at the same central laboratory (Lifechem
Laboratories, Woodland Hills, CA, USA). Intact PTH was mea-
sured by immunoradiometric assay using the Nichols Institute Kit
(San Juan Capistrano, CA, USA); serum Ca, P and albumin were
measured using a Hitachi 736 analyzer (Hitachi, Indianapolis, IN,
USA). Serum levels of 1,25(OH)2-vitamin D2 and i,25(OH)2-
vitamin D1 were determined by radioreceptor assay after high-
pressure liquid chromatography at Bone Care International
(Madison, WI, USA).
The data were expressed as mean SEM, unless stated other-
wise. For parametric data, one way ANOVA or ANOVA with
repeated measures were performed where indicated [151. For
non-parametric data the Kruskal-Wallis and Friedman tests were
used. The Bonferroni t-test or student t-test were used to test for
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Fig. 1. Mean levels of serum intact PTH during the last four weeks of
washout and treatment with la-hydroxy-vitamin D2 (laD2), with the mean
weekly dosage of laD shown as solid bars. Data are mean SEM. P values
differ from baseline: * < ()Q5; **p < 0.025, and *P < 0.01.
significance. A value of P < 0.05 was considered significant.
Multiple linear regression analysis was used to determine if any
relationship existed between the changes in either serum Ca or
serum P and the changes in serum iPTH levels. The statistical
analyses were performed using the Statview IV for Macintosh
(Abacus Concepts, Inc.).
Results
The average serum iPTH levels and dosage of 1D2 are shown
in Figure 1. At baseline (Week 0), the mean serum iPTH level,
defined as the average of the four serum iPTH levels obtained
during washout, was 672 70 pg/mi for the 24 patients, with a
range of 359 to 1521 pg/mI and median of 496 pg/mi. By the end
of the first week of treatment, the serum iPTH levels had
decreased significantly, and there was a steady decline throughout
the remainder of the treatment period. Figure 2 shows the serum
iPTH levels in individual patients. These include the baseline,
lowest and final (Week 12) serum iPTH levels. The lowest serum
iPTH values in 12 patients were below 130 pg/mi, the lower limit
of the "target" iPTH range; those in 9 patients were within the
target range of 130 to 250 pg/mi. Three patients had lowest serum
iPTH levels above 250 pg/mI, ranging from 317 to 514 pg/nil.
Thus, 21 of the 24 or 87.5% of the patients reached the target
iPTH. This lowest serum iPTH level averaged 165 23 pg/mI with
a range of 19 to 514 pg/mI, and this represented a suppression of
75.4% (range of 48 to 96%) from the baseline value (P < 0.001
compared to baseline).
At the end of the treatment period, the mean serum iPTH was
289 36 pg/mI, with a range of 19 to 772 pg/mI (P < 0.01
compared to baseline). The serum iPTH levels were below the
target range in 5 patients and within the range in 8 patients. The
values exceeded 250 pg/mI in 11 patients, seven of whom had
stopped laD2 treatment temporarily according to the protocol for
dosage adjustment. The rate of response of serum iPTH to laD2
was variable; six patients showed a reduction of iPTH by more
than 50% within two weeks, while the others required an average
of 6.1 weeks before serum iPTH fell more than 50%.
The effects of treatment with laD2 on serum calcium and
phosphorus are shown in Figure 3. The baseline serum Ca level,
defined as the average of values over the last four weeks of
washout, averaged 8.8 0.18 mg/dl. There was a slow increase in
serum Ca, with the mean value being significantly above the
baseline on the third, seventh, and twelfth weeks of treatment
(P < 0.025). At the end of the treatment period, the mean serum
Ca was 9.5 0.21 mg/dl. There were 13 episodes of hypercalce-
mia, defined as a serum Ca above 10.5 mg/dl, in 10 patients during
treatment with laD2; the highest value was 12.3 mg/dl and
median, 10.9 mg/dl. There was a single episode of hypercalcemia
of 10.9 mg/dl during the washout period. For the total group,
there were 4.7 episodes of hypercalcemia per 100 weeks of
treatment, compared to 0.53 episodes per 100 weeks during the
washout (P < 0.02). When treatment with laD2 was stopped or
reduced, the serum Ca had decreased to 10.5 mg/dl or below
within three to seven days. The mean serum phosphorus level at
baseline was 5.0 0.30 mg/dl, compared to 5.1 0.32 mg/dl at the
end of treatment (P = NS). There were 13 episodes of hyper-
phosphatemia, defined as a serum P above 6.9 mg/dl, in 6 patients
during the washout period (maximum value, 9.9 mg/dl, and
median, 7.7 mg/dl); this compares to 30 episodes in 18 patients
during treatment (maximum value, 9.4 mg/dl, and median, 7.6
mg/dl). This represents 6.9 episodes of hyperphosphatemia per
100 weeks of observation during washout and 10.1 episodes per
100 weeks during treatment, these frequencies did not differ
significantly.
The predialysis serum levels of 1,25(OH)2D2 are shown in
Figure 4. During the washout period, the levels of 1,25(OH)2D2
were below the detection limit of 5 pg/mI in 41 samples from 22
patients, and measurable levels, ranging from 5.9 to 8.4 pg/mI,
were found in seven samples from 5 patients. The mean serum
level of 1,25(OH)2D2 were 14.2 6.8 pg/mI (median, 14.3 pg/mI)
in patients receiving laD2, 8 xg per week and 20.1 16.3 pg/mi,
median, 17 pg/mI in those who had received 12 xg per week. The
serum level of 1,25(OH)2D2 was 43.4 25.2 pg/mI (median, 40.5
pg/nil) when the dosage was 28 j.g per week. During the washout
period, the serum levels of I ,25(OH)2D3 were below the detection
limits (< 5 pg/mI) in 27 samples from 16 patients, and levels
ranged from 5.1 to 21.3 pg/mI in the 21 measurable samples,
mean, 10.4 0.79 pg/mI. During treatment with laD2, the serum
levels of 1,25(OH)2D3 were undetectable in 82 samples from 23
patients, and the measurable levels ranged from 5.1 to 17.7 pg/mI
(mean, 9.6 0.53 pg/mI) in 40 samples from 20 patients.
No significant complications were noted during the treatment
period. When hypercaicemia or hyperphosphatemia did occur,
there were no symptoms, and the elevated values responded to a
reduction in the dose of laD2 and/or changes in the dose of
phosphate binding agents. The average doses of phosphate
binder, defined by the quantity of elemental calcium, given during
the washout and treatment periods were 4.0 0.6 g/day and 4.1
0.6 g/day, respectively (P NS).
In accordance with the pre-established protocol, treatment with
laD., was discontinued 21 times in 15 patients. Therapy was
interrupted 15 times because serum iPTH had decreased below
the target range, in 5 instances because of unacceptable hyper-
phosphatemia, with serum P ranging from 8.3 to 9.9 mg/dI, and
because of an increase in serum Ca to 12.3 mg/dI on one occasion.
In the 12 instances when the lowest iPTH value occurred before
the end of treatment, the length of time that elapsed before
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Fig. 2. Serum iPTH levels in individual patients,
showing the pre-treatment level (basal), the lowest
value (nadir) during treatment with la-hydroxy-
vitamin D2 (laD2), and the serum iPTH level at
the end of 12 weeks (final). A. Sixteen patients
with a nadir serum iPTH occurring before
treatment ended and with subsequent
interruption of treatment and reduction of
dosage. B. Eight patients whose nadir serum
iPTH value was simultaneous with the final
level. The rectangles indicate the desired target
range for serum iPTH with treatment (130 to
250 pg/mI).
treatment was resumed varied from 3 to 14 days, with a median of
seven days. In these patients, the serum iPTH level averaged
104 8.6 pg/mI before the treatment with laD, was stopped; the
mean iPTH value rose to 288 38.5 (P < 0.001) when the levels
were next measured after 4 to 12 days (median time, seven days).
At these respective times, the serum Ca levels had decreased from
10.26 0.28 to 9.58 0.25 mg/dl, (P < 0.003); the mean serum
P levels at these times were 5.43 0.40 and 5.39 0.39 mg/dl,
respectively (P = NS). In 12 other instances, there was a reduction
in dosage without an interruption of therapy, which was done
because serum iPTH fell within the target range or had decreased
markedly to approach the target range. Among the 14 patients
initially treated with 4 j.tg three times per week, the frequency of
dosing was increased to daily in 6 patients; it remained the same
in two and was reduced in the remaining six. For the total group
of 24 patients, the maximum dose of laD2 averaged 23.3 1.52
jrg per week. The weekly dose of I aD2 was 16.7 1.73 jig per
week when the serum 1PTI-I was at its nadir and 14.2 1.67 jig per
week during the last week of treatment.
During treatment with laD2, there were low inverse correla-
tions between the change in serum Ca and the change in serum
iPTH (r = 0.32, P < 0.000 1) and also between the change in serum
Ca and the change in serum P (r = 0.19, P < 0.001). There was a
low level direct correlation between the change in serum P and the
change in serum iPTH (r = 0.27, P < 0.001).
Discussion
The present study is the first to demonstrate that laD2 is
efficacious in lowering serum levels of intact PTH in hemodialysis
patients with moderate to severe secondary hyperparathyroidism.
The present study differs from earlier trials with vitamin D sterols
in that treatment was adjusted to achieve a specific range of intact
PTH levels that have been associated with normal or minimally
increased rates of bone formation [11—14]. The serum iPTH levels
fell by 48 to 96% (mean, 75.4%) in all 24 patients at some time
during the study, and by the end of study were, on the average,
51% lower than the pre-treatment values. Twenty-one (87.5%) of
the 24 patients reached the therapeutic target range of serum
iPTH at some time during the study. Moreover, these reductions
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Fig. 4. Serum levels of 1,25 (OH) ,-vitamin D2 before and during treatment
0 I with la-hydroxy-vitamin D2 (laD2) according to the weekly dose of laD2; theI horizontal bar indicates mean values. During the pre-treatment period, 40
—4 —2 0 2 4 6 8 10 12 values were below the limits of detection; 7 values were measurable. With
a dose of 8 jig per week, one of 19 measurements was below the limits of
Time, weeks detection; with a dose of 12 xg per week, 5 of 48 measurements were
below the detection level. During treatment with 28 jig per week of 1aD,
Fig. 3. Mean values for serum Ca (W and P (•) over the last four weeks of all 36 serum samples contained measurable amounts. -
washout and during treatment with la-hydroxy-vitamin D2 (laD2). Data are
mean SEM; the values differ from the baseline, < 0.025.
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in iPTH occurred with only modest increments in serum Ca and
with no significant change in serum P.
It is important to consider how the present observations
compare with previous reports of the effects of calcitriol treatment
in patients with ESRD. Although there are no studies that
compare the two sterols, a comparison of data obtained in the
present study to those obtained in comparable studies using
treatment with calcitriol may provide some insight into the
relative efficacy of the two sterols. Twelve prospective studies that
included 309 adult patients treated with oral or intravenous
calcitriol for at least three months have been published since 1989.
Excluded are reports that included patients with only mild sec-
ondary hyperparathyroidism, as indicated by average intact PTH
levels below 450 pg/mI [16, 17].
Also, excluded are studies that utilized a PTH immunoassay
which does not permit comparison with results using the intact
PTH assay [18, 19]. Several reports included number of patients of
10 or less, and these results must be viewed with some caution
[20—23].
In several studies, aluminum-containing gels, either alone or in
conjunction with calcium carbonate or calcium acetate, were
utilized for the control of hyperphosphatemia [20, 21, 24—27]. It is
likely that the use of aluminum-containing phosphate binders
rather than larger doses of calcium salts would permit the use of
higher doses of calcitriol with less risk of hypercalcemia; however,
there would be a potential risk of aluminum accumulation. In
several of these studies [20, 21, 24, 26], the average maximal
suppression of iPTH was greater than 50%, with a range from 59
to 84%. These compare favorably with the average suppression of
73% in the present study using laD2. In the two multicenter
studies, the maximum iPTH suppression was less than 50% [25,
27]. Therefore, 24% of the patients in the large multicenter study
of Gallieni et al [251 were classified as treatment failures, largely
because hypercalcemia or a rise in the Ca x P product limited the
dose that was given. In the multicenter study of Quarles et al [27],
47% were treatment failures. Here, high serum phosphorus levels
frequently necessitated a dosage reduction, which contributed in a
major way to the incidence of treatment failure. In the therapeutic
trials done in a single dialysis center and providing data on all
patients treated [20, 21, 24, 26], 89% of the patients showed more
than 50% suppression of the iPTH levels. In several other trials,
only calcium carbonate or calcium acetate were utilized as phos-
phate-binding agents [8, 22, 23, 28—30J. Dressler et a! [31]
achieved impressive maximal PTH suppression by 92.1% in the 17
patients reported, hut the average serum Ca at the time of
maximum PTH suppression was 11.3 mg/dl, and the average
serum P was 8.2 mg/dl at the time of last follow-up. Gonella et al
[30] were forced to reduce calcitriol dosage in 12 of 14 treated
patients because of hypercalcemia and/or hyperphosphatemia, but
the serum calcium and phosphorus levels are not reported. In all
patients, the serum Ca X P product exceeded 65 (mg/dl X mg/dl)
and in half it exceeded 75. Malberti, Surian and Cosci [22]
achieved excellent suppression of PTH, but they noted hypercal-
cemia, defined as an ionized Ca above 1.40 mmol/liter, in 37% of
145 measurements during treatment. Moreover, the total serum
Ca at the end of four months treatment was 11.1 mg/dl. Liach,
Hcrvas and Cerezo [23] studied 10 patients with severe secondary
hyperparathyroidism, with pre-treatment intact PTH of 1466
116 (sEM) pg/rn!. Serum iPTH was reduced by 88% after 16
months of treatment. However, the calcitriol was not discontin-
ued, unless the serum Ca exceeded 12.0 mg/dl and the drug was
continued with a reduced dose when the serum Ca was 11.5 to
11.9 mg/dl. Oettinger, Oliver and Macon [28] gave intravenous
calcitriol to 69 patients with serum iPTH levels above 300 pg/mI
for six months. The average iPTH fell by approximately 43%, and
the criteria for discontinuing the drug and for dosage adjustment
and the maximum serum levels of Ca and P for these patients were
not included in their report.
One-alpha(OH)-vitamin D3, or alfacalcidol, has been utilized
extensively in Canada, Europe and Japan for the management of
renal osteodystrophy. Since it undergoes the same hepatic 25-
hydroxylation as I aD2, the results with use of this sterol are of
interest. A few studies have used measurements of intact PTH,
permitting comparison with the present results. Brandi et al [32]
gave thrice weekly intravenous alfacalcidol, 1 jtg to 4 j.g per
hemodialysis, to 21 hemodialysis patients for three months. Serum
iPTH fell by 67% in the patients; however, the pretreatment
average iPTH was only modestly elevated to 231 pg/ml and the
values were within the normal range in 5 patients. Despite
increased doses of aluminum gels, serum P rose during the study
from 5.89 to 7.49 mg/dl; also, serum Ca rose from 9.2 to 10.4
mg/dl. The three patients with serum iPTH levels above 1100
pg/mI failed to respond. In a multicenter study, Ljunghall et al [33]
gave intravenous alfacaleidol for 12 weeks to 51 patients in doses
of I to 4 g per hemodialysis session. There was a 60% reduction
of iPTH levels from an average pre-treatment value of 255 pg/ml;
serum P rose from 6.42 to 7.41 mg/dl and the serum Ca from 8.8
to 10.0 mgldl. The reduction of iPTH was inversely related to the
rise in serum Ca (r =
—0.51). Finally, Moriniere et al [34]
reported results in 17 patients selected because their hyperpara-
thyroidism had been resistant to daily oral alfacaleidol. The
patients were treated with intermittent intravenous alfacalcidol, I
to 4 tg with each dialysis, for six months. Calcium carbonate was
the only phosphate-binding agent utilized, and dialysate Ca was
reduced to 2.5 mEq/liter. The dose of calcium carbonate was
increased from approximately 3.1 to 4.9 g elemental calcium per
day to maintain the serum P levels below 6.3 mgldl, although the
range of values was not given. Mean serum iPTH fell from 486 to
125 pg/mI, a 74% reduction, after six months of treatment. The
mean serum Ca rose from 9.4 to 10.1 mg/dl, but the range of
values was not given.
The present multieenter evaluation of laD2 therapy, which
utilized a target intact PTH for reducing or temporarily discon-
tinuing treatment, achieved maximal suppression of intact PTH
that approached the results of the best of the trials utilizing
intravenous calcitriol in conjunction with calcium-based phos-
phate binding agents. Moreover, this occurred with only slight
increases in serum Ca. In the present study, the incidence of even
mild hypercalcemia, and hyperphosphatemia were relatively low
despite the initial "high" dose of laD2 used. Indeed, the incidence
of hyperphosphatemia and the required dosages of phosphate
binders did not differ during the washout and treatment periods.
Calcitriol has been recognized to play an important role in the
treatment of renal hyperparathyroidism for more than 15 years.
Conventional therapy with daily oral calcitriol is limited by the
occurrence of hypercalcemia and hyperphosphatemia, findings
that have prompted the widespread use of intermittent intrave-
nous calcitriol therapy as an alternative mode of treatment [35].
Despite the initial promising results of pulse dosing with intrave-
nous calcitriol, there appear to be few differences in the efficacy or
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side effects of calcitriol between the intravenous and intermittent
oral administration of calcitriol [16, 24, 27].
Because of the low therapeutic index with calcitriol, whether
given intravenously or orally, there has been a search for other
vitamin D analogs that can suppress PTH secretion without
causing hypercalcemia and hyperphosphatemia. In vitamin D-
deficient rats, laD2 was equipotent to laD1 in reversing the
features of vitamin D-deflciency, that is, stimulating intestinal
calcium and phosphate transport, enhancing calcification of the
epiphyseal plate, elevating serum phosphorus and in antirachitic
activity [7]. However, there was far less toxicity of I aD2 than laD3
when they are given in large doses to both rats and mice [8]. With
a long-term maintenance dose, I aD was four to five times less
toxic than laD3 in normal rats [8] and produced hypercalcemia
with one-third the activity as laD5 in normal mice [9]. In 7 to 15
postmenopausal osteopenic women, laD2 was given in doses
ranging from 0.5 to 10.0 gIday; there was an increase of serum
osteocalcin, an index of osteoblastic activity, at doses above 2.0
tg/day; urinary calcium rose slightly with 4 j.tg/day and hypercal-
ciuria occurred only with doses of 5 jig/day and above. There was
no increase in the excretion of urinary hydroxyproline with laD2,
an observation consistent with no increase in bone resorption [10].
These observations provided the rationale for evaluating the
safety and efficacy of I aD2 in hemodialysis patients with second-
ary hyperparathyroidism.
In the present study, the time required for a response to laD2
was variable. The rapidity of response did not appear to be
influenced by the initial levels of serum iPTH. The data suggest
that significant responses occurred as late as eight weeks after
initiation of treatment. Therefore, in future studies, if a patient
does not respond within four weeks of treatment, it would seem
appropriate to continue therapy for at least four more weeks
before concluding that the patient is resistant to treatment with
laD2.
The mechanism by which I aD2 suppresses PTH is unknown. A
rise in serum Ca during treatment undoubtedly contributed to the
decline in serum iPTH. However, there was a poor correlation
between the changes in the levels of serum Ca and those of serum
iPTH; most patients exhibited a significant lowering of serum
iPTH levels prior to a rise in their serum Ca. It is likely that laD2
directly suppresses PTH secretion by the parathyroid gland. It is
believed that after hydroxylation by the liver to 1,25(OH)2D2,
I aD acts in a manner similar to calcitriol, binding to vitamin D
receptors in the parathyroid and gut. The active form of I aD2 may
directly suppress PTH secretion by parathyroid cells in an analo-
gous manner to that of calcitriol, Further studies are needed to
determine the precise mechanism of action of this vitamin D
analog.
The present study, with each hemodialysis patient acting as his
own control, demonstrates that laD2 is efficacious and safe in the
treatment of hemodiatysis patients with moderate to severe
secondary hyperparathyroidism. These results suggest that 1 aD
may he a reasonable alternative to calcitriol in uremic patients
with secondary hyperparathyroidism.
Hypercalcemia was noted, particularly as serum iPTH became
overly suppressed, but it was of minimal significance and it was
easily managed with adjustment of the dose of IaD2 and/or that
of the calcium-based phosphate-binding agents. The incidence of
hyperphosphatemia was not different between washout and treat-
ment. Future studies utilizing IaD2 are needed to establish its
optimal dosing and to understand the mechanism by which I aD2
suppresses PTH. Moreover, future studies comparing the efficacy
and safety of laD2 with either ealcitriol or la-hydroxy vitamin D1
(alfacalcidol) are clearly warranted.
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